Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids

Michael S. Boosalis, Tohru Ikuta, Betty Sue Pace, Silvana Da Fonseca, Gary L. White, Douglas V. Faller, Susan P. Perrine

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Short-chain fatty acids, such as butyrate and propionate, induce fetal globin gene expression and are under clinical investigation in the β- hemoglobinopathies. Limitations of the short-chain fatty acids as therapeutics include their rapid metabolism and a tendency to induce cell growth arrest if administered for prolonged periods. In studies described here, the cellular effects of other inducers of fetal globin, phenoxyacetic acid and derivatives of short-chain fatty acids and cinnamic acids, were investigated in the human erythroid cell line K562, the IL-3 dependent multi- lineage cell line (32D), and in mice and primates. Several test compounds supported 32D cell proliferation despite a 50-fold depletion of IL-3, which resulted in growth arrest and apoptotic death in control cells. The degree of proliferation induced by certain test compounds was similar to the degree of proliferation induced by Erythropoietin and G-CSF in the cells. Eight of ten compounds induced γ globin mRNA in K562 cells. A 2.5 to 6-fold increase in reticulocytosis was observed vivo in mice treated with two prototype compounds. Pharmacokinetic studies of three prototype compounds demonstrated millimolar plasma concentrations after single oral doses for many hours in primates. These findings identify orally bioavailable compounds which induce γ globin gene expression and hematopoietic cell proliferation through an activity which partially abrogates requirements for IL-3. Such compounds provide potential for oral therapeutics which stimulate proliferation of hematopoietic cells of multiple lineages, as well as including fetal globin.

Original languageEnglish (US)
Pages (from-to)434-442
Number of pages9
JournalBlood Cells, Molecules and Diseases
Volume23
Issue number3
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Globins
Interleukin-3
Carboxylic Acids
Cell Proliferation
Volatile Fatty Acids
Primates
Reticulocytosis
Gene Expression
Cell Line
Hemoglobinopathies
Erythroid Cells
K562 Cells
Butyrates
Propionates
Cell Lineage
Granulocyte Colony-Stimulating Factor
Growth
Erythropoietin
Pharmacokinetics
In Vitro Techniques

Keywords

  • Cell proliferation
  • Globin genes
  • Growth factors
  • Hematopoiesis
  • Mice
  • Primates

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this

Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids. / Boosalis, Michael S.; Ikuta, Tohru; Pace, Betty Sue; Fonseca, Silvana Da; White, Gary L.; Faller, Douglas V.; Perrine, Susan P.

In: Blood Cells, Molecules and Diseases, Vol. 23, No. 3, 01.01.1997, p. 434-442.

Research output: Contribution to journalArticle

Boosalis, Michael S. ; Ikuta, Tohru ; Pace, Betty Sue ; Fonseca, Silvana Da ; White, Gary L. ; Faller, Douglas V. ; Perrine, Susan P. / Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids. In: Blood Cells, Molecules and Diseases. 1997 ; Vol. 23, No. 3. pp. 434-442.
@article{132fb08e7c374fa7bb0dd512a4582b91,
title = "Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids",
abstract = "Short-chain fatty acids, such as butyrate and propionate, induce fetal globin gene expression and are under clinical investigation in the β- hemoglobinopathies. Limitations of the short-chain fatty acids as therapeutics include their rapid metabolism and a tendency to induce cell growth arrest if administered for prolonged periods. In studies described here, the cellular effects of other inducers of fetal globin, phenoxyacetic acid and derivatives of short-chain fatty acids and cinnamic acids, were investigated in the human erythroid cell line K562, the IL-3 dependent multi- lineage cell line (32D), and in mice and primates. Several test compounds supported 32D cell proliferation despite a 50-fold depletion of IL-3, which resulted in growth arrest and apoptotic death in control cells. The degree of proliferation induced by certain test compounds was similar to the degree of proliferation induced by Erythropoietin and G-CSF in the cells. Eight of ten compounds induced γ globin mRNA in K562 cells. A 2.5 to 6-fold increase in reticulocytosis was observed vivo in mice treated with two prototype compounds. Pharmacokinetic studies of three prototype compounds demonstrated millimolar plasma concentrations after single oral doses for many hours in primates. These findings identify orally bioavailable compounds which induce γ globin gene expression and hematopoietic cell proliferation through an activity which partially abrogates requirements for IL-3. Such compounds provide potential for oral therapeutics which stimulate proliferation of hematopoietic cells of multiple lineages, as well as including fetal globin.",
keywords = "Cell proliferation, Globin genes, Growth factors, Hematopoiesis, Mice, Primates",
author = "Boosalis, {Michael S.} and Tohru Ikuta and Pace, {Betty Sue} and Fonseca, {Silvana Da} and White, {Gary L.} and Faller, {Douglas V.} and Perrine, {Susan P.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1006/bcmd.1997.0162",
language = "English (US)",
volume = "23",
pages = "434--442",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids

AU - Boosalis, Michael S.

AU - Ikuta, Tohru

AU - Pace, Betty Sue

AU - Fonseca, Silvana Da

AU - White, Gary L.

AU - Faller, Douglas V.

AU - Perrine, Susan P.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Short-chain fatty acids, such as butyrate and propionate, induce fetal globin gene expression and are under clinical investigation in the β- hemoglobinopathies. Limitations of the short-chain fatty acids as therapeutics include their rapid metabolism and a tendency to induce cell growth arrest if administered for prolonged periods. In studies described here, the cellular effects of other inducers of fetal globin, phenoxyacetic acid and derivatives of short-chain fatty acids and cinnamic acids, were investigated in the human erythroid cell line K562, the IL-3 dependent multi- lineage cell line (32D), and in mice and primates. Several test compounds supported 32D cell proliferation despite a 50-fold depletion of IL-3, which resulted in growth arrest and apoptotic death in control cells. The degree of proliferation induced by certain test compounds was similar to the degree of proliferation induced by Erythropoietin and G-CSF in the cells. Eight of ten compounds induced γ globin mRNA in K562 cells. A 2.5 to 6-fold increase in reticulocytosis was observed vivo in mice treated with two prototype compounds. Pharmacokinetic studies of three prototype compounds demonstrated millimolar plasma concentrations after single oral doses for many hours in primates. These findings identify orally bioavailable compounds which induce γ globin gene expression and hematopoietic cell proliferation through an activity which partially abrogates requirements for IL-3. Such compounds provide potential for oral therapeutics which stimulate proliferation of hematopoietic cells of multiple lineages, as well as including fetal globin.

AB - Short-chain fatty acids, such as butyrate and propionate, induce fetal globin gene expression and are under clinical investigation in the β- hemoglobinopathies. Limitations of the short-chain fatty acids as therapeutics include their rapid metabolism and a tendency to induce cell growth arrest if administered for prolonged periods. In studies described here, the cellular effects of other inducers of fetal globin, phenoxyacetic acid and derivatives of short-chain fatty acids and cinnamic acids, were investigated in the human erythroid cell line K562, the IL-3 dependent multi- lineage cell line (32D), and in mice and primates. Several test compounds supported 32D cell proliferation despite a 50-fold depletion of IL-3, which resulted in growth arrest and apoptotic death in control cells. The degree of proliferation induced by certain test compounds was similar to the degree of proliferation induced by Erythropoietin and G-CSF in the cells. Eight of ten compounds induced γ globin mRNA in K562 cells. A 2.5 to 6-fold increase in reticulocytosis was observed vivo in mice treated with two prototype compounds. Pharmacokinetic studies of three prototype compounds demonstrated millimolar plasma concentrations after single oral doses for many hours in primates. These findings identify orally bioavailable compounds which induce γ globin gene expression and hematopoietic cell proliferation through an activity which partially abrogates requirements for IL-3. Such compounds provide potential for oral therapeutics which stimulate proliferation of hematopoietic cells of multiple lineages, as well as including fetal globin.

KW - Cell proliferation

KW - Globin genes

KW - Growth factors

KW - Hematopoiesis

KW - Mice

KW - Primates

UR - http://www.scopus.com/inward/record.url?scp=0031427861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031427861&partnerID=8YFLogxK

U2 - 10.1006/bcmd.1997.0162

DO - 10.1006/bcmd.1997.0162

M3 - Article

VL - 23

SP - 434

EP - 442

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 3

ER -